Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2022 09:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Study site initiations in the United States for a randomized Phase 2/3 study of CTX-009 with paclitaxel in patients with Biliary Tract Cancers (BTC) and a Phase 2 of CTX-009 in patients with...
November 08, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics to Present at Upcoming Investment Conferences

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
November 02, 2022 09:06 ET | Source: Compass Therapeutics

Compass Therapeutics Announces $80 Million Private Placement

BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), (“Compass”), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to...
October 11, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA® (pembrolizumab)

BOSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
September 09, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

BOSTON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
August 02, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics to Present at the 13th Annual Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
August 01, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Phase 2/3 trial of CTX-009 (DLL4 X VEGF-A bispecific) and paclitaxel in biliary tract cancer (BTC) anticipated to begin in the United States in Q3 2022A Phase 2 trial of CTX-009 as a monotherapy in...
May 31, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

BOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
May 23, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference

BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
May 09, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to expand the ongoing Phase 2 study in patients with biliary tract...